Literature DB >> 24789672

Human Wharton's jelly stem cells, its conditioned medium and cell-free lysate inhibit the growth of human lymphoma cells.

Hao Daniel Lin1, Chui Yee Fong, Arijit Biswas, Mahesh Choolani, Ariff Bongso.   

Abstract

Several groups have reported that primitive mesenchymal stem cells from the gelatinous matrix of the Wharton's jelly of the human umbilical cord (hWJSCs) possess tumoricidal properties and inhibit the growth of solid tumours such as human mammary carcinoma, ovarian carcinoma and osteosarcoma. This unique characteristic led to the hypothesis that hWJSCs serve as a natural defence against migrating cancer cells from mother to fetus thus explaining why tumorigenesis in the fetus is rare. However, it is not known whether non-solid malignant hematopoietic cells are also inhibited by hWJSCs and what the exact tumoricidal mechanisms are. We therefore evaluated the influence of hWJSCs and its extracts on Burkitt's lymphoma cells. Cell proliferation (BrdU and Ki67+), viability (MTT) and cell death (Annexin V-Propidium iodide and live/dead) assays showed significant inhibition of lymphoma cell growth after 48 h exposure to hWJSCs or its extracts compared to controls. Increased cell death was observed at sub-G1 and S and decreased proliferation at G2/M phases of the mitotic cycle. Superoxide dismutase and hydrogen peroxide activity were significantly increased and glutathione peroxidase significantly decreased in treated lymphoma cells. Time lapse imaging and confocal z-stack images showed yellow fluorescent in situ hybridization (FISH) signals of lymphoma cell Y chromosomes within the cytoplasm of female red labelled hWJSCs. We hypothesize that the growth of lymphoma cells is inhibited by the molecules secreted by hWJSCs that use oxidative stress pathways to induce cell death followed by engulfment of the apoptotic remains of the lymphoma cells by the hWJSCs.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24789672     DOI: 10.1007/s12015-014-9514-3

Source DB:  PubMed          Journal:  Stem Cell Rev Rep        ISSN: 2629-3277            Impact factor:   5.739


  78 in total

Review 1.  Drugs toxic to the bone marrow that target the stromal cells.

Authors:  I Guest; J Uetrecht
Journal:  Immunopharmacology       Date:  2000-02

Review 2.  Transplantation of umbilical cord-derived mesenchymal stem cells as a novel strategy to protect the central nervous system: technical aspects, preclinical studies, and clinical perspectives.

Authors:  Jérémie Dalous; Jérome Larghero; Olivier Baud
Journal:  Pediatr Res       Date:  2012-02-08       Impact factor: 3.756

3.  A toxicity study of multiple-administration human umbilical cord mesenchymal stem cells in cynomolgus monkeys.

Authors:  Youwei Wang; Zhi-Bo Han; Jinling Ma; Conglin Zuo; Jie Geng; Wei Gong; Yunxia Sun; Hongzhen Li; Bin Wang; Lei Zhang; Yanan He; Zhong Chao Han
Journal:  Stem Cells Dev       Date:  2011-11-22       Impact factor: 3.272

4.  Human umbilical cord Wharton's jelly stem cells and its conditioned medium support hematopoietic stem cell expansion ex vivo.

Authors:  C Y Fong; K Gauthaman; S Cheyyatraivendran; H D Lin; A Biswas; A Bongso
Journal:  J Cell Biochem       Date:  2012-02       Impact factor: 4.429

Review 5.  Intraplacental choriocarcinoma in a term placenta with both maternal and infantile metastases: a case report and review of the literature.

Authors:  Jianping Liu; Lina Guo
Journal:  Gynecol Oncol       Date:  2006-09-26       Impact factor: 5.482

6.  Human Wharton's jelly stem cells have unique transcriptome profiles compared to human embryonic stem cells and other mesenchymal stem cells.

Authors:  Chui-Yee Fong; Li-Ling Chak; Arijit Biswas; Jee-Hian Tan; Kalamegam Gauthaman; Woon-Khiong Chan; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2011-03       Impact factor: 5.739

7.  Naïve human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo.

Authors:  Rie Ayuzawa; Chiyo Doi; Raja Shekar Rachakatla; Marla M Pyle; Dharmendra Kumar Maurya; Deryl Troyer; Masaaki Tamura
Journal:  Cancer Lett       Date:  2009-03-13       Impact factor: 8.679

Review 8.  Mesenchymal stem cells: angels or demons?

Authors:  Rebecca S Y Wong
Journal:  J Biomed Biotechnol       Date:  2011-07-24

9.  Reconstruction of hematopoietic inductive microenvironment after transplantation of VCAM-1-modified human umbilical cord blood stromal cells.

Authors:  Yao Liu; Xing-hua Chen; Ying-jian Si; Zhong-jun Li; Lei Gao; Li Gao; Cheng Zhang; Xi Zhang
Journal:  PLoS One       Date:  2012-02-23       Impact factor: 3.240

10.  Microvesicles derived from human umbilical cord Wharton's jelly mesenchymal stem cells attenuate bladder tumor cell growth in vitro and in vivo.

Authors:  Shuai Wu; Guan-Qun Ju; Tao Du; Ying-Jian Zhu; Guo-Hua Liu
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

View more
  19 in total

Review 1.  Mesenchymal stem/stromal cell-derived exosomes in regenerative medicine and cancer; overview of development, challenges, and opportunities.

Authors:  Ali Hassanzadeh; Heshu Sulaiman Rahman; Alexander Markov; Judi Januadi Endjun; Angelina Olegovna Zekiy; Max Stanley Chartrand; Nasrin Beheshtkhoo; Mohammad Amin Jadidi Kouhbanani; Faroogh Marofi; Marzieh Nikoo; Mostafa Jarahian
Journal:  Stem Cell Res Ther       Date:  2021-05-21       Impact factor: 6.832

2.  Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton's Jelly Mesenchymal Stem Cell Conditioned Medium.

Authors:  Daniel Hao Lin; Arijit Biswas; Mahesh Choolani; Chui-Yee Fong; Ariff Bongso
Journal:  Stem Cell Rev Rep       Date:  2017-12       Impact factor: 5.739

3.  A peculiar molecular profile of umbilical cord-mesenchymal stromal cells drives their inhibitory effects on multiple myeloma cell growth and tumor progression.

Authors:  Sabino Ciavarella; Anna Caselli; Antonella Valentina Tamma; Annalisa Savonarola; Giuseppe Loverro; Roberto Paganelli; Marco Tucci; Franco Silvestris
Journal:  Stem Cells Dev       Date:  2015-03-11       Impact factor: 3.272

Review 4.  The Clinical Applications of Endometrial Mesenchymal Stem Cells.

Authors:  Wanyun Zuo; Bingyu Xie; Chenglong Li; Yuhan Yan; Yangyi Zhang; Wei Liu; Jufang Huang; Dan Chen
Journal:  Biopreserv Biobank       Date:  2017-12-21       Impact factor: 2.300

5.  Redox-Active Mn Porphyrin-based Potent SOD Mimic, MnTnBuOE-2-PyP(5+), Enhances Carbenoxolone-Mediated TRAIL-Induced Apoptosis in Glioblastoma Multiforme.

Authors:  Yulyana Yulyana; Artak Tovmasyan; Ivy A W Ho; Kian Chuan Sia; Jennifer P Newman; Wai Hoe Ng; Chang Ming Guo; Kam Man Hui; Ines Batinic-Haberle; Paula Y P Lam
Journal:  Stem Cell Rev Rep       Date:  2016-02       Impact factor: 5.739

Review 6.  Wharton's jelly derived mesenchymal stem cells: future of regenerative medicine? Recent findings and clinical significance.

Authors:  Ilona Kalaszczynska; Katarzyna Ferdyn
Journal:  Biomed Res Int       Date:  2015-03-15       Impact factor: 3.411

7.  Human endometrial mesenchymal stem cells exhibit intrinsic anti-tumor properties on human epithelial ovarian cancer cells.

Authors:  Shixia Bu; Qian Wang; Qiuwan Zhang; Junyan Sun; Biwei He; Charlie Xiang; Zhiwei Liu; Dongmei Lai
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

Review 8.  Human-derived normal mesenchymal stem/stromal cells in anticancer therapies.

Authors:  Cheng Zhang; Shi-Jie Yang; Qin Wen; Jiang F Zhong; Xue-Lian Chen; Andres Stucky; Michael F Press; Xi Zhang
Journal:  J Cancer       Date:  2017-01-01       Impact factor: 4.207

Review 9.  Importance of the origin of mesenchymal (stem) stromal cells in cancer biology: "alliance" or "war" in intercellular signals.

Authors:  Noemi Eiro; Maria Fraile; Silvia Fernández-Francos; Rosario Sánchez; Luis A Costa; Francisco J Vizoso
Journal:  Cell Biosci       Date:  2021-06-10       Impact factor: 7.133

10.  Wharton's Jelly-Derived Mesenchymal Stromal Cells and Fibroblast-Derived Extracellular Matrix Synergistically Activate Apoptosis in a p21-Dependent Mechanism in WHCO1 and MDA MB 231 Cancer Cells In Vitro.

Authors:  Kevin Dzobo; Matjaz Vogelsang; Nicholas E Thomford; Collet Dandara; Karlien Kallmeyer; Michael S Pepper; M Iqbal Parker
Journal:  Stem Cells Int       Date:  2016-01-10       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.